Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 112 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX				Phase III, Phase II				D8480C00013 Eudract Number 2005-003440-66, NCT00384176
	Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Chemotherapy				Phase III, Phase II				CRAD001C2241 NCT00419159
	FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer				Phase III, Phase II				STX0206 NCT00724503
	FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma				Phase III, Phase II				STX0207 NCT00735241
	Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer				Phase III				CALGB-C80405 C80405, SWOG-C80405, NCT00265850
	Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.				Phase III				EFC5505 SR57746A, NCT00305188
	Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in theTreatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen				Phase III				EFC10262 EudraCT 2007-000820-42, NCT00561470
	Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer				Phase II, Phase I				3c-03-19 NCT00159484
	Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic or Locally Advanced Colorectal Cancer or Other Solid Tumors That Cannot Be Removed by Surgery				Phase II, Phase I				CASE-1205 NCI-7325, 7325, NCT00296062
	Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer				Phase II, Phase I				3C-05-3 NCT00336141


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute